

Michael Pfaller

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9336718/michael-pfaller-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14
papers

2,371
citations

11
h-index

15
g-index

15
ext. papers

2,642
ext. citations

4.8
avg. IF

4.22
L-index

#	Paper	IF	Citations
14	Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).. <i>Journal of Clinical Microbiology</i> , 2022 , e0244921	9.7	0
13	Application of Culture-Independent Rapid Diagnostic Tests in the Management of Invasive Candidiasis and Cryptococcosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2015 , 1, 217-251	5.6	7
12	Candidemia surveillance in Iowa: emergence of echinocandin resistance. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014 , 79, 205-8	2.9	38
11	The changing epidemiology of healthcare-associated candidemia over three decades. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012 , 73, 45-8	2.9	234
10	The PATH (Prospective Antifungal Therapy) Alliance registry and invasive fungal infections: update 2012. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012 , 73, 293-300	2.9	173
9	Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance) registry, 2004-2008. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012 , 74, 323-31	2.9	271
8	Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against <i>Candida glabrata</i> with and without fks mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5875-82	5.9	36
7	Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant <i>Candida</i> isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 1891-5	5.9	17
6	Emerging Resistance to Azoles and Echinocandins: Clinical Relevance and Laboratory Detection. <i>Current Fungal Infection Reports</i> , 2010 , 4, 186-195	1.4	5
5	Reduction of fluconazole susceptibility of <i>Candida albicans</i> in APECED patients due to long-term use of ketoconazole and miconazole. <i>Scandinavian Journal of Infectious Diseases</i> , 2008 , 40, 904-7		32
4	Decreased susceptibility of <i>Candida albicans</i> to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 889-92	5.1	42
3	<i>Candida albicans</i> and <i>Candida glabrata</i> clinical isolates exhibiting reduced echinocandin susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 2892-4	5.9	156
2	Attributable mortality of nosocomial candidemia, revisited. <i>Clinical Infectious Diseases</i> , 2003 , 37, 1172-7	11.6	879
1	Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. <i>Pediatric Infectious Disease Journal</i> , 2000 , 19, 319-24	3.4	480